PDCD1 and neoplasm: Smoking history, particularly current smoking, therefore appears to be a determinant of a favorable outcome of PD-1/PD-L1 therapy in NSCLC, possibly related to the suppressive effects of smoking on pulmonary immune function (52), as well as to increased tumor mutational load and neoantigenicity mediated by smoke-derived carcinogens.